LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer

被引：0
|
作者：
Xi Jin
Li-Ping Ge
Da-Qiang Li
Zhi-Ming Shao
Gen-Hong Di
Xiao-En Xu
Yi-Zhou Jiang
机构：
[1] Fudan University Shanghai Cancer Center,Department of Breast Surgery
[2] Fudan University Shanghai Cancer Center,Cancer Institute
[3] Fudan University,Department of Oncology, Shanghai Medical College
[4] Fudan University Shanghai Cancer Center,Precision Cancer Medicine Center
[5] Key Laboratory of Breast Cancer in Shanghai,undefined
来源：
Molecular Cancer | / 19卷
关键词：
Breast cancer; lncRNA TROJAN; CDK4/6 inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
    Chica-Parrado, M. Rosario
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Mahoney, Timothy
    Mauer, Elizabeth
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2023, 83 (05)
  • [22] PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
    Chen, Anran
    Kim, Beom-Jun
    Mitra, Aparna
    Vollert, Craig T.
    Lei, Jonathan T.
    Fandino, Diana
    Anurag, Meenakshi
    Holt, Matthew V.
    Gou, Xuxu
    Pilcher, Jacob B.
    Goetz, Matthew P.
    Northfelt, Donald W.
    Hilsenbeck, Susan G.
    Marshall, C. Gary
    Hyer, Marc L.
    Papp, Robert
    Yin, Shou-Yun
    De Angelis, Carmine
    Schiff, Rachel
    Fuqua, Suzanne A. W.
    Ma, Cynthia X.
    Foulds, Charles E.
    Ellis, Matthew J.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (10) : 1494 - 1510
  • [23] Mechanisms of resistance to CDK4/6 inhibition in ER plus breast cancer
    Lee, N. V.
    Eisele, K. J.
    Chionis, J.
    Yuan, J.
    Zhu, Z.
    Liu, C.
    Li, D.
    Olson, P. A.
    Fantin, V.
    Arndt, K. T.
    Shields, D. J.
    VanArsdale, T. L.
    CANCER RESEARCH, 2016, 76
  • [24] Unveiling mechanisms of CDK4/6 inhibitor resistance in ER plus breast cancer models with acquired resistance
    Li, Bin
    Liu, Gaoxiang
    Ni, Ting
    Shi, Wenting
    Gu, Qingyang
    CANCER RESEARCH, 2024, 84 (06)
  • [25] Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors
    Hall, Claire R.
    Bisi, John E.
    Strum, Jay C.
    CANCER RESEARCH, 2019, 79 (13)
  • [26] The CDK4/CDK6 inhibitor abemaciclib inhibits transcriptional targets which facilitate growth in ER plus breast cancer cells
    McNulty, Ann M.
    Burke, Teresa
    Dempsey, Jack A.
    Marchal, Christophe C.
    Schade, Andrew E.
    Szpurka, Hadrian P.
    Dowless, Michele S.
    Stephens, Jennifer
    Stephens, Jennifer
    Edmondson, Denise
    Stayrook, Keith
    Caldwell, William C.
    Buchanan, Sean
    Merzoug, Farhana F.
    Beckmann, Richard P.
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [27] Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Mai, Nicholas
    dos Anjos, Carlos H.
    Razavi, Pedram
    Safonov, Anton
    Patil, Sujata
    Chen, Yuan
    Drago, Joshua Z.
    Modi, Shanu
    Bromberg, Jacqueline F.
    Dang, Chau T.
    Liu, Dazhi
    Norton, Larry
    Robson, Mark
    Chandarlapaty, Sarat
    Jhaveri, Komal
    NPJ BREAST CANCER, 2024, 10 (01)
  • [28] Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)
    Galardi, F.
    Biagioni, C.
    De Luca, F.
    Curigliano, G.
    Minisini, A. M.
    Bonechi, M.
    Moretti, E.
    Risi, E.
    Migliaccio, I.
    McCartney, A.
    Benelli, M.
    Romagnoli, D.
    Conti, V.
    Biganzoli, L.
    Di Leo, A.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S18 - S18
  • [29] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer andtriple negative breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Liu, Qiao
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah
    CANCER RESEARCH, 2023, 83 (07)
  • [30] MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
    de Leeuw, Renee
    McNair, Christopher
    Schiewer, Matthew J.
    Neupane, Neermala Poudel
    Brand, Lucas J.
    Augello, Michael A.
    Li, Zhen
    Cheng, Larry C.
    Yoshida, Akihiro
    Courtney, Sean M.
    Hazard, E. Starr
    Hardiman, Gary
    Hussain, Maha H.
    Diehl, J. Alan
    Drake, Justin M.
    Kelly, Wm. Kevin
    Knudsen, Karen E.
    CLINICAL CANCER RESEARCH, 2018, 24 (17) : 4201 - 4214
12345